Gastrointestinal Cancer Clinical Trials & Research at Providence Medical Group
Gastrointestinal (GI) cancers encompass a group of malignancies affecting
the digestive system, including the esophagus, stomach, liver, pancreas,
gallbladder, and intestines. These cancers are among the most prevalent
and deadly worldwide, often diagnosed at advanced stages due to the lack
of early symptoms. As such, there is a critical need for innovative treatments
to improve patient outcomes.
Clinical trials play a vital role in the advancement of GI cancer therapies.
These studies are designed to evaluate the safety and efficacy of new
treatments, which may include chemotherapy, targeted therapies, immunotherapies,
and surgical techniques. By conducting rigorous trials, researchers can
identify better ways to treat, manage, and potentially cure GI cancers.
Providence Medical Group is currently enrolling patients for the following
Gastrointestinal studies:
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment agent: Repotrectinib (TPX-0005) oral medication
Physician:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
tracy.foster@stjoe.org // 707-521-3830
Study Resources:
https://www.clinicaltrials.gov/study/NCT03093116
Sponsor: Turning Point Therapeutics, Inc.
Location: Providence Cancer Center, Santa Rosa, CA
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability,
Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination
with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing
Claudin 18.2 (CLARITY-PanTumour01)